Explore a selection of our essential drug information below, or:
Overview
- Description
- A medication used to treat snake bites from North American coral snake.
- Description
- A medication used to treat snake bites from North American coral snake.
- DrugBank ID
- DB13883
- Type
- Biotech
- Clinical Trials
- Phase 0
- 0
- Phase 1
- 0
- Phase 2
- 0
- Phase 3
- 0
- Phase 4
- 0
Identification
- Summary
Coral snake (micrurus fulvius) immune globulin antivenin (equine) is a mixture of antibodies used to treat venomous snake bites from Micrurus fulvius (North American Coral Snake).
- Generic Name
- Coral snake (micrurus fulvius) immune globulin antivenin (equine)
- DrugBank Accession Number
- DB13883
- Background
North American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment of envenomation caused by North American coral snake bites. It is intravenously administered so that the antivenin binds to and neutralizes coral snake venom.
The antivenin is a refined, concentrated, and lyophilized preparation of serum globulins obtained by fractionating blood from healthy horses that have been immunized with eastern coral snake (Micrurus fulvius fulvius) venom Label. Prior to lyophilization, the product contains 0.25% phenol and 0.005% thiomerosal (mercury derivative) Label.
- Type
- Biotech
- Groups
- Approved, Experimental
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Antivenin (micrurus fulvius)
- Antivenin,micrurus fulvius
- Coral snake (micrurus fulvius) antivenin (equine)
- Coral snake (micrurus fulvius) immune antivenin (equine)
- Coral snake antivenin
- Coral Snake Immune Globulin (Horse)
- North american coral snake (micrurus fulvius) antivenin (equine)
- North American coral snake antivenin
- North American Coral Snake Antivenin (Equine)
- North american coral snake antivenin (micrurus fulvius) (equine)
Pharmacology
- Indication
This particular antivenin is indicated only for the treatment of envenomation caused by bites from Eastern coral snakes (Micrurus fulvius fulvius) and Texas coral snakes (Micrurus fulvius tenere) Label,3. The agent will not neutralize the venom of Arizona (Sonoran) coral snakes (Micruroides euryxanthus) or that of South American species Label,3.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Reversal of Venom poisoning caused by micrurus fulvius •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
North American Coral Snake Antivenin (Equine) is standardized for potency in mice in terms of its LD50 neutralizing capacity per milliliter as determined by intravenous injection of a graded series of mixtures of North American Coral Snake Antivenin (Equine) with M. f. fulvius venom Label,3. Based on this assay system, the reconstituted contents of each vial (10 mL) will neutralize about 250 mouse LD50 or approximately 2 mg of M. f. fulvius venom Label,3.
- Mechanism of action
North American Coral Snake Antivenin (Equine) is a preparation of serum globulins obtained by fractionating blood from healthy horses that have been immunized with eastern coral snake (Micrurus fulvius fulvius) venom Label,3.
When the antivenin is appropriately administered intravenously, it essentially functions like an injection of antibodies that directly bind to and neutralize coral snake venom that has entered the bloodstream due to any kind of coral snake bite Label,3.
- Absorption
As the antivenin is essentially an emergency antivenom medication that is administered intravenously in hopes of eliciting an as immediate as possible coral snake venom neutralization in a patient's bloodstream, it is generally assumed that the emergency injection is absorbed entirely.
- Volume of distribution
The formal prescribing information for this antivenin describes itself as a preparation containing serum golbulins Label,3 obtained from the fractionated blood of health horses immunized with the necessary venom. If the term 'serum globulins' is taken to mean that this antivenin consists of whole IgG immunoglobulin molecules, then various reviews of antibody preparations suggest that such equine IgG antivenoms generally demonstrate a lower volume of distribution in comparison to antivenoms comprised of Fab or F(ab')2 fragments and has been known to potentially exist within the range of 162 +/- 1.9 mL/kg in a rabbit model 1.
- Protein binding
Information regarding the protein binding of this antivenin agent is not readily available, although its predominant mechanism of action revolves around binding specifically to Micrurus fulvius fulvius and Micrurus fulvius tenere coral snake venom.
- Metabolism
The formal prescribing information for this antivenin describes itself as a preparation containing serum golbulins Label,3 obtained from the fractionated blood of health horses immunized with the necessary venom. If the term 'serum globulins' is taken to mean that this antivenin consists of whole IgG immunoglobulin molecules, then various reviews of antibody preparations suggest that such IgG components undergo much catabolism at the gut and liver in a mouse model 1. Any such IgG molecules with intact carbohydrate containing Fc portions may also experience carbohydrate-specific uptake mechanisms associated with mononuclear phagocyte activity in the liver and other organs 1. Additionally, although it has been observed that the liver and spleen demonstrate the highest IgG catabolism activity in the rat model on a weight basis, in terms of total catabolism, the peripheral tissues, skin, and muscle play the dominant role, indicating that the catabolism of antibodies may occur all throughout the body system 1.
- Route of elimination
The formal prescribing information for this antivenin describes itself as a preparation containing serum golbulins Label,3 obtained from the fractionated blood of health horses immunized with the necessary venom. If the term 'serum globulins' is taken to mean that this antivenin consists of whole IgG immunoglobulin molecules, then various reviews of antibody preparations suggest that such IgG containing formulations may have the majority of its IgG components eliminated mainly via extrarenal mechanisms 1.
- Half-life
The formal prescribing information for this antivenin describes itself as a preparation containing serum golbulins Label,3 obtained from the fractionated blood of health horses immunized with the necessary venom. If the term 'serum globulins' is taken to mean that this antivenin consists of whole IgG immunoglobulin molecules, then various reviews of antibody preparations suggest that such equine IgG formulations demonstrate an intermediate distribution half-life ranging from 5.22 +/- 0.98 hours to 5.98 +/- 0.67 hours and an elimination half-life ranging from 42.66 +/- 2.04 hours to 46.4 +/- 4.8 hours in a rabbit model 1.
- Clearance
The formal prescribing information for this antivenin describes itself as a preparation containing serum golbulins Label,3 obtained from the fractionated blood of health horses immunized with the necessary venom. If the term 'serum globulins' is taken to mean that this antivenin consists of whole IgG immunoglobulin molecules, then various reviews of antibody preparations suggest that such equine IgG formulations demonstrate a rate of clearance ranging anywhere from 0.36 +/- 0.06 mL/h/kg to 5.46 +/ 0.6 mL/h/kg 1.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Patients sensitive to antivenin or horse serum may develop anaphylaxis Label. Therefore, it is essential that prior to any antivenin administration a proper skin test be performed, interpreted, and therapy modified if indicated Label. Anaphylaxis seen with antivenins of equine origin may result in an immediate reaction (shock) usually occurring within 30 minutes Label. Signs and symptoms may develop before the needle of administration is even withdrawn from the patient and can include apprehension, flushing, itching, urticaria; edema of the face, tongue, and throat; cough, dyspnea, cyanosis, vomiting, collapse, and possibly even cardiac arrest or death Label.
Constant attendance and observation for untoward response is mandatory whenever horse serum is administered intravenously so that, should such occur, injection may be discontinued and appropriate treatment instituted immediately Label.
Even if it is appropriate for a patient to be administered the antivenin, the most common adverse reactions observed after treatment with the agent has been anaphylaxis and serum sickness, vomiting, and abdominal pain Label.
LD50 values are available for animal models such as the rat, in which the oral LD50 is documented to be 317 mg/kg and the dermal LD50 as 525 mg/kg MSDS.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Antivenin (micrurus Fulvius) Injection, powder, for solution 1 g/10mL Intravenous Wyeth Pharmaceuticals Company 1967-06-01 2001-08-31 US 
North American Coral Snake Antivenin (Equine) Injection, powder, for solution 250 [arb'U]/10mL Intravenous Wyeth Pharmaceuticals Llc, a Subsidiary of Pfizer Inc. 2016-10-12 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- Y605XBM2GL
- CAS number
- Not Available
References
- General References
- Gutierrez JM, Leon G, Lomonte B: Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation. Clin Pharmacokinet. 2003;42(8):721-41. doi: 10.2165/00003088-200342080-00002. [Article]
- Leon G, Stiles B, Alape A, Rojas G, Gutierrez JM: Comparative study on the ability of IgG and F(ab')2 antivenoms to neutralize lethal and myotoxic effects induced by Micrurus nigrocinctus (coral snake) venom. Am J Trop Med Hyg. 1999 Aug;61(2):266-71. [Article]
- Dailymed: North American Coral Snake Antivenin (Equine) - coral snake (microbus fulvous) immune globulin antivenin (equine) injection, powder, for solution Label [Link]
- External Links
- FDA label
- Download (69.9 KB)
- MSDS
- Download (42.3 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intravenous 1 g/10mL Injection, powder, for solution Intravenous 250 [arb'U]/10mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at September 07, 2017 19:03 / Updated at June 19, 2021 00:27